Targeted renal therapy: a potential weapon in the battle against CIN.
Boyle
Jonathan R
JR
Cambridge University Hospitals, Addenbrooke's Hospital, Cambridge, UK. jonathan.boyle@addenbrookes.nhs.uk
D000527:Alprostadil / Q000008:administration & dosage; D002404:Catheterization / Q000009:adverse effects / Q000295:instrumentation; D003287:Contrast Media / Q000009:adverse effects*; D016503:Drug Delivery Systems / Q000009:adverse effects / Q000295:instrumentation; D004867:Equipment Design; D018818:Fenoldopam / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D020097:Natriuretic Peptide, Brain / Q000008:administration & dosage; D020011:Protective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D011859:Radiography; D012077:Renal Artery / Q000000981:diagnostic imaging; D051437:Renal Insufficiency / Q000139:chemically induced / Q000517:prevention & control* / Q000628:therapy; D012107:Research Design; D017693:Sodium Bicarbonate / Q000008:administration & dosage; D016896:Treatment Outcome
D003287:Contrast Media; D020011:Protective Agents; D020097:Natriuretic Peptide, Brain; D017693:Sodium Bicarbonate; D000527:Alprostadil; D018818:Fenoldopam